USD 2386.72 million
Report ID:
SQMIG35I2114 |
Region:
Global |
Published Date: February, 2024
Pages:
242
|Tables:
200
|Figures:
80
Psychedelic Drugs Market size was valued at USD 2386.72 million in 2019 and is poised to grow from USD 2706.71 million in 2023 to USD 6401.95 million by 2031, growing at a CAGR of 13.3% in the forecast period (2024-2031).
The development of psychedelic drugs, as well as increased awareness of the importance of treating mental health issues, are major factors driving market growth over the forecast period. The need to manage excessive stress, anxiety, and other mental disorders is critical to the market growth. Because psychedelic drugs provide new mechanisms for treating mental illness, some have shown promise, while others have been ineffective. Government initiatives, alliances, and mental health awareness programmers are expected to drive market growth during the forecast period.
Mental health issues are one of the major factors driving market growth over the forecast period, as mental health issues such as anxiety and depression, psychosis, and some forms of panic attacks necessitate treatment with psychedelic drugs. According to the State of Mental Health in America 2022 report, the number of youths experiencing a severe major depressive episode (MDE) increased by 197,000 from the 2021 dataset. Thus, an increase in the prevalence of depressive disorders leads to an increase in demand for psychedelic drugs, which boosts market growth over the forecast period.
As a result of increased awareness about the importance of treating mental illnesses, increased research and development of psychedelic drugs, and growing acceptance of psychedelic drugs for depression, the market is expected to grow over the forecast period. However, rising psychedelic drug side effects and a stringent regulatory framework will restrict market growth over the forecast period. While there are still legal and regulatory obstacles to overcome, as well as concerns about safety and potential side effects, the growing interest in psychedelic drugs as a potential new area of growth and investment, indicates that this industry will be one to watch in the coming years.
US Psychedelic Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Market Size
USD 2386.72 million
Largest Segment
Gamma-Hydroxybutyric Acid
Fastest Growth
Gamma-Hydroxybutyric Acid
Growth Rate
13.3% CAGR
To get more reports on the above market click here to Buy The Report
Global Psychedelic Drugs Market is segmented based on Source, Type, Drugs, Application, Route of Administration, End User, Distribution Channel and region. Based on Source the market is segmented into Synthetic and Natural. Based on Type the market is segmented into Empathogens, Dissociative, Others. Based on Drugs the market is segmented into Gamma-Hydroxybutyric Acid, Ketamine, Psilocybin, Others. Based on Application the market is segmented into Narcolepsy, Treatment Resistant Depression, Major Depressive Disorder, Opiate Addiction, Post-Traumatic Stress Disorder, Others. Based on Route of Administration the market is segmented into Oral, Inhalation, Injectable. Based on End User the market is segmented into Hospital, Speciality Clinics, Homecare, Others. Based on Distribution Channel The market is segmented into Hospitals Pharmacy, Retail Pharmacy, Online Pharmacy. Based on region the global Psychedelic Drugs Market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.
Psychedelic Drugs Market Analysis by Drug
The gamma-hydroxybutyric acid segment will be the most popular in 2021, as Xyrem from Jazz Pharmaceutical is one of the almost psychedelic medications on the market, with a large market share and belonging to the drug class. It is a Schedule I controlled substance, which means it must be prescribed by a physician and closely monitored. GHB is used to treat excessive daytime sleepiness in its prescription form. In a few cases, gamma-hydroxybutyric acid has also been used to treat alcoholism and drug withdrawal. GHB is used to treat narcolepsy and, less commonly, alcoholism; however, its efficacy in comparison to other alcoholism pharmacotherapies is unknown. It is sometimes used off-label to treat bromalin. GHB is the active ingredient in the pharmaceutical sodium oxidate (Xylem). The Food and Drug Administration in the United States has approved sodium oxidate for the treatment of cataplexy and excessive daytime sleepiness (EDS) in people with narcolepsy.
To get detailed analysis on other segments, Request For Free Sample Report
North America is expected to continue to dominate the global psychedelic drugs market during the forecast period. The FDA's recognition of advanced drug fusion portfolios obtained from psychedelic drugs has aided the growth of the North American market. Furthermore, the presence of key market players in this region, as well as increased investment in research and development activities, are supporting market growth. The European Union is the second-largest market after North America in terms of psychedelic drug market share.
The Asia Pacific market for psychedelic drugs is also expected to grow slowly. The sale of FDA-approved psychedelic drugs in the country has increased research activities. The increasing presence of key pharmaceutical players in the country for oncology-related treatment and ketamine psychedelic drugs is expected to pave the way for the development of psychedelic drugs for medicinal purposes.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Psychedelic Drugs Market Drivers
Acceptance of Psychedelic Drugs for Treating Depression is Growing
Depression and mental disorders have increased globally
Psychedelic Drugs Market Restraints
High cost of psychedelic drugs
Request Free Customization of this report to help us to meet your business objectives.
The major players are actively implementing growth strategies, such as product launches, acquisitions, and collaborations, to contribute to the market's growth. For instance, Cybin, a biotechnology company focused on progressing psychedelic therapeutics, announced the launch of the EMBARK psychedelic facilitatory training course in October 2021. This program offers the foundational training required for psychedelic clinical trial facilitators to provide skilled and ethical care to participants receiving psychedelic treatment.
Psychedelic Drugs Market Top Player’s Company Profiles
Psychedelic Drugs Market Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates and Analyses the Data collected by means of Primary Exploratory Research backed by the robust Secondary Desk research.
According to our global Psychedelic Drugs market analysis, we found that the development of psychedelic drugs, as well as increased awareness of the importance of treating mental health issues, are key drivers of market growth over the forecast period. The need to manage excessive stress, anxiety, and other mental disorders is critical to the market growth. Because psychedelic drugs provide new mechanisms for treating mental illness, some have shown promise, while others have been ineffective. Government initiatives, alliances, and mental health awareness programmes are expected to drive market growth during the forecast period.
Report Metric | Details |
---|---|
Market size value in 2023 | USD 2386.72 million |
Market size value in 2031 | USD 6401.95 million |
Growth Rate | 13.3% |
Forecast period | 2024-2031 |
Forecast Unit (Value) | USD Million |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
Historical Year | 2019 |
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Psychedelic Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Psychedelic Drugs Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Psychedelic Drugs Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Psychedelic Drugs Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Psychedelic Drugs Market size was valued at USD 2386.72 million in 2019 and is poised to grow from USD 2706.71 million in 2023 to USD 6401.95 million by 2031, growing at a CAGR of 13.3% in the forecast period (2024-2031).
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35I2114
sales@skyquestt.com
USA +1 351-333-4748